Abstract Background Disseminated tumor cells (DTCs) can enter a dormant state and cause no symptoms in cancer patients. On the other hand, the dormant DTCs can reactivate and cause metastases progression and lethal relapses. In prostate cancer (PCa), relapse can happen after curative treatments such as primary tumor removal. The impact of surgical removal on PCa dissemination and dormancy remains elusive. Furthermore, as dormant DTCs are asymptomatic, dormancy-induction can be an operational cure for preventing metastases and relapse of PCa patients. Methods We used a PCa subcutaneous xenograft model and species-specific PCR to survey the DTCs in various organs at different time points of tumor growth and in response to tumor removal. We de...
The primary tumor microenvironment is inherently important in prostate cancer (PCa) initiation, grow...
INTRODUCTION: Tumor populations may selectively colonize bone that is being actively remodeled. In p...
Prostate cancer is the second leading cause of cancer death in men in the UK. Around 30% of patients...
Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the disease pro...
<div><p>Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the dis...
It has been reported that disseminated tumor cells (DTCs) can be found in the majority of prostate c...
It has been reported that disseminated tumor cells (DTCs) can be found in the majority of prostate c...
Advanced prostate cancer (PCa) patients with bone metastases are treated with androgen pathway direc...
Breast cancer can recur in patients months to decades after initial diagnosis and treatment. There i...
Advanced-stage prostate cancer (PCa) patients are often diagnosed with bone metastases. Bone metasta...
Tumor metastasis can occur years after an apparent cure due to a phenomenon known as metastatic tumo...
Tumors have already threatened human life and health for centuries, especially the recurrent of bone...
The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attri...
The primary tumor microenvironment is inherently important in prostate cancer (PCa) initiation, grow...
Background: Bone forming metastases are a common and disabling consequence of prostate cancer (CaP)....
The primary tumor microenvironment is inherently important in prostate cancer (PCa) initiation, grow...
INTRODUCTION: Tumor populations may selectively colonize bone that is being actively remodeled. In p...
Prostate cancer is the second leading cause of cancer death in men in the UK. Around 30% of patients...
Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the disease pro...
<div><p>Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the dis...
It has been reported that disseminated tumor cells (DTCs) can be found in the majority of prostate c...
It has been reported that disseminated tumor cells (DTCs) can be found in the majority of prostate c...
Advanced prostate cancer (PCa) patients with bone metastases are treated with androgen pathway direc...
Breast cancer can recur in patients months to decades after initial diagnosis and treatment. There i...
Advanced-stage prostate cancer (PCa) patients are often diagnosed with bone metastases. Bone metasta...
Tumor metastasis can occur years after an apparent cure due to a phenomenon known as metastatic tumo...
Tumors have already threatened human life and health for centuries, especially the recurrent of bone...
The latency associated with bone metastasis emergence in castrate-resistant prostate cancer is attri...
The primary tumor microenvironment is inherently important in prostate cancer (PCa) initiation, grow...
Background: Bone forming metastases are a common and disabling consequence of prostate cancer (CaP)....
The primary tumor microenvironment is inherently important in prostate cancer (PCa) initiation, grow...
INTRODUCTION: Tumor populations may selectively colonize bone that is being actively remodeled. In p...
Prostate cancer is the second leading cause of cancer death in men in the UK. Around 30% of patients...